Preterm Birth is a growing global healthcare crisis and the leading cause of infant death and morbidity within the 1st month of life (while also being recognized as a significant contributing factor to the increasing occurrence of a number of lifelong crippling diseases including autism, cerebral palsy, blindness, deafness and others). Existing surgical and pharmaceutical emergency and rescue treatment options, which are costly, invasive and address only a narrow scope of contributing maternal conditions, are being rejected by Payers, since none have proven efficacy. Moreover, those options are not available to most of the world's suffering population. Beyond the immeasurable human tragedy, global socioeconomic consequences of Preterm Birth exceed $52 billion annually. CSD is expected to be a Class I or ‘low scale’ Class II device by the FDA (meaning the regulatory pathway will be less complicated than for many medical devices).
ViaTechMD has an extraordinary proof of efficacy foundation, and believes there will be very strong Payer motivation to address reimbursement policies. The company's development also supports a very strong business model, promising sizable returns to those who might help bring this important technology to the tens of millions of families who are in such desperate need each year. Inquires should be directed to: Ben Booher, Sr. President ViaTechMD@aol.com
